DelMar Pharmaceuticals’ (DMPI) “Purchase” Rating Restated at Maxim Group

DelMar Pharmaceuticals’ (DMPI) “Purchase” Rating Restated at Maxim Group

Maxim Group restated their buy rating on shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in a research report released on Thursday morning. The brokerage currently has a $11.00 target price on the stock.

“DelMar announced that a new P2 study of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) has initiated with MD Anderson. The single- arm study will enroll 48 patients that have unmethylated MGMT and are Avastin naïve. The endpoint of the study will be overall survival (OS) vs. historical control.”,” Maxim Group’s analyst wrote.

Separately, Aegis assumed coverage on DelMar Pharmaceuticals in a research report on Thursday, January 5th. They set a buy rating and a $16.00 target price for the company. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $10.50.

Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) opened at 4.69 on Thursday. The company has a 50-day moving average price of $3.63 and a 200 day moving average price of $5.29. DelMar Pharmaceuticals has a 52 week low of $2.88 and a 52 week high of $10.87.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Related posts

Leave a Comment